信必可联合复方甲氧那明治疗支气管哮喘的疗效及肺功能变化的临床分析

Clinical Analysis of Curative Effect of Symbicort Turbuhaler Combined with Compound Methoxyphenamine in Treatment of Patients with Bronchial Asthma and Lung Function Changes

目的:探讨信必可联合复方甲氧那明治疗支气管哮喘的效果及肺功能变化的临床分析。方法:回顾性分析2014年8月-2016年3月在本院呼吸科支气管哮喘急性发作的60例住院患者的临床资料,按照给药方式不同分为复方组和单一组,各30例。单一组遵医嘱给予信必可治疗,复方组在单一组的基础上遵医嘱给予复方甲氧那明胶囊治疗,治疗周期均为4周。观察记录两组患者治疗前后的临床症状、肺功能及血清炎性因子IL-6、TNF-α水平。结果:治疗4周后,复方组咳嗽有效率明显高于单一组,差异有统计学意义(P<0.05);复方组的喘息和喘鸣音症状治疗有效率虽均高于单一组,但差异均无统计学意义(P>0.05)。治疗4周后,两组患者的FEV_1、PEFR、FEV_1/FVC均较治疗前有明显改善,差异均有统计学意义(P<0.05),且复方组的FEV_1、PEFR、FEV_1/FVC均明显高于单一组,差异均有统计学意义(P<0.05)。治疗4周后,复方组患者的血清IL-6和TNF-α水平均低于单一组,差异均有统计学意义(P<0.05)。两组的不良反应发生率比较,差异无统计学意义(P>0.05)。结论:应用信必可联合复方甲氧那明治疗支气管哮喘,可明显改善患者临床症状、肺功能水平,降低血液炎性因子水平,效果显著,且不良反应轻微,安全度较高,值得临床推广应用。

Objective： To explore the clinical analysis and efficacy of Symbicort Turbuhaler and Compound Methoxyphenamine in treatment of bronchial asthma and pulmonary function changes.Method： 60 bronchial asthma patients were retrospectively analyzed from August 2014 to March 2016 from in our hospital, according to the dosing methods, all patients were divided into compound group and single group, 30 cases in each group. The single group was given Symbicort Turbuhaler, on the basis of single group, the compound group was given Compound Methoxyphenamine Capsule, the treatment period was 4 weeks.The clinical symptoms, pulmonary function, serum inflammatory factors IL-6 and TNF-α levels were observed and recorded before and after treatment between the two groups.Result： After 4 weeks of treatment, the effective rate of cough in compound group was significantly higher than that of single group, the difference was statistically significant （ P〈0.05 ） ; the effective rate of beathing and symptoms of wheezing in compound group were higher than those in single group, but the differences were not statistically significant （ P〉0.05 ） .After 4 weeks of treatment, the FEVt, PEFR and FEV1/FVC of the patients in the two groups were significantly improved compared with those before treatment, the differences were statistically significant （ P〈0.05 ）, the FEV1, PEFR, FEV1/FVC in compound group were significantly higher than those in single group, the differences were statistically significant （ P〈0.05 ） .After treatment for 4 weeks, the serum IL-6 and TNF-α in compound group were lower than those in single group, the differences were statistically significant （ P〈0.05 ） .There was no significant difference in the incidence of adverse reactions between the two groups （ P〉0.05 ） .Conclusion： The application Symbicort Turbuhaler combined with Compound Methoxyphenamine treatment of bronchial asthma, can significantly improve the clinical symptoms, pulmonary function, reduce blood levels Of inflammatory factors, the effect is significant, and mild adverse reaction, high safety, it is worthy of clinical application.